A Phase Ib Study Of Cetuximab Combined With Fruquintinib In The Previously Treated Ras/Braf Wild-Type Metastatic Colorectal Cancer: The Preliminary Result Of Cefru Study

Y. Li,X. Chen,Y. H. Liu, X. Qu,Y. S. Ye, S. D. Sun, Y. D. Chen,H. B. Zhang

ANNALS OF ONCOLOGY（2021）

Cited 0|Views2

No score

Abstract

The standard third-line treatment of metastatic colorectal cancer (mCRC) is regorafenib, fruquintinib, or TAS-102. However, the efficacy was not satisfied. We conducted a phase Ib /Ⅱa clinical study to evaluate the safety and efficacy of fruquintinib plus cetuximab in mCRC（TPS151, 2021 ASCO GI） This time we reported the phase Ib dose-escalation study results.

Translated text

Key words

metastatic colorectal cancer,colorectal cancer,cetuximab,fruquintinib,wild-type

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined